Lineage Cell Therapeutics Inc. — Director's Dealing 2012

Mar 19, 2012

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: BIOTIME INC (BTX)
CIK: 0000876343
Period of Report: 2012-03-19

Reporting Person: GARCIA PETER S (Chief Financial Officer)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2012-03-19	Common Shares, no par value	P	1700	$4.679	Acquired	3700	Direct
2012-03-19	Common Shares, no par value	P	3300	$4.674	Acquired	7000	Direct

Holdings (Derivative)

Security	Exercise Price	Expiration	Underlying	Shares	Ownership
Option to Purchase Common Shares	$4.17	2018-10-02	Common Shares (200000)	200000	Direct

Footnotes

F1: Does not include shares that may be acquired upon the exercise of certain stock options.

F2: 1/48th of the number of options will vest at the end of each full month of employment after October 3, 2011